Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

China Medical In-Licenses Dry Eye, Psoriasis Treatments from India's Sun Pharma

publication date: Jun 28, 2019

China Medical System of Shenzhen in-licensed greater China rights for two prescription drugs from India's Sun Pharma, a treatment for dry eye and a biologic treatment for psoriasis. The two patented drugs will be the first Sun Pharma products available in China. CMS will make an upfront payment to Sun Pharma, plus pay regulatory/sales milestones and royalties on sales. Further details are confidential. CMS, which will be responsible for China regulatory approvals of the products, will have rights to the products for 15 years. More details....

Stock Symbols: (HK: 0867) (NSE: SUNPHARMA, BSE: 524715)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.